C19H22N4O6.C2HF3O2
Neat
402.41 114.02
1799711-25-3; E3 ligase Ligand-Linker Conjugates 16; Thalidomide-O-amido-C4-NH2 (TFA); MFCD31560484; N-(4-aminobutyl)-2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl)oxy)acetamide 2, 2, 2-trifluoroacetate; N-(4-aminobutyl)-2-[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-4-yl]oxyacetamide;2, 2, 2-trifluoroacetic acid; N-(4-aminobutyl)-2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl)oxy)acetamide TFA salt; N-(4-aminobutyl)-2-[2-(2, 6-dioxo-3-piperidyl)-1, 3-dioxo-isoindolin-4-yl]oxy-acetamide;2, 2 and 2-trifluoroacetic acid; orb1299533; SCHEMBL17839640; SCHEMBL29493524; C21H23F3N4O8; XVUPBWSTMLHSHM-UHFFFAOYSA-N; EX-A3865; AKOS037655171; AT18334; CS-7755; Thalidomide-O-amido-C4-amine TFA Salt; Cereblon Ligand-Linker Conjugates 6 TFA; E3 ligase Ligand-Linker Conjugates 16?
N-(4-aminobutyl)-2-[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-4-yl]oxyacetamide;2, 2 and 2-trifluoroacetic acid
InChI=1S/C19H22N4O6.C2HF3O2/c20-8-1-2-9-21-15(25)10-29-13-5-3-4-11-16(13)19(28)23(18(11)27)12-6-7-14(24)22-17(12)26;3-2(4,5)1(6)7/h3-5,12H,1-2,6-10,20H2,(H,21,25)(H,22,24,26);(H,6,7)